2019-003550-88: A Phase I/II dose-escalation trial investigating the oncolytic virus TMV-018 in combination with a chemotherapy precursor (5-Fluorocytosine) or an immunotherapeutic agent (anti-PD-1 therapy) in patients with tumors of the gastrointestinal tract in terms of safety, clinical activity as well as pharmacokinetics and pharmacodynamics. |
|
|
| Not yet recruiting | 1/2 | 39 | Europe | TMV-018, TMV-018, Solution for infusion | Themis Bioscience GmbH, Themis Biosience GmbH | Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Diseases [C] - Cancer [C04] | | | | |